On September 20, 2023, TOLREMO therapeutics AG announced that it has completed its Series A financing, bringing the total amount raised to USD 39 m (CHF 34.1 m). BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.

TOLREMO's mission is to stop non-genetic cancer drug resistance as it emerges by dismantling cancer's earliest defenses to targeted therapies, thus surmounting a universal challenge for current and future targeted treatments.

The Homburger team was led by Dieter Gericke and Margrit Marti and comprised Francesco Bernasconi, Stefan Luginbühl, Thierry Burckhardt and Claudine Schär (all Corporate / M&A; Healthcare / Life Sciences) as well as Stefan Oesterhelt (Tax).